BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2019 7:58:39 AM | Browse: 970 | Download: 2064
 |
Received |
|
2019-02-03 14:52 |
|
Peer-Review Started |
|
2019-02-06 06:18 |
|
First Decision by Editorial Office Director |
|
2019-03-14 02:51 |
|
Return for Revision |
|
2019-03-15 02:49 |
|
Revised |
|
2019-03-21 18:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-04-04 08:26 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-04-10 21:42 |
|
Articles in Press |
|
2019-04-10 21:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-14 00:31 |
|
Publish the Manuscript Online |
|
2019-05-14 07:58 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nicole Loo, Eric Lawitz, Naim Alkhouri, Jennifer Wells, Carmen Landaverde, Angie Coste, Rossalynn Salcido, Michael Scott and Fred Poordad |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| AbbVie |
B15-791 |
|
| Corresponding Author |
Fred Poordad, MD, Attending Doctor, Professor, Academic and Clinical Affairs, Texas Liver Institute, 607 Camden Street, San Antonio, TX 78215, United States. poordad@txliver.com |
| Key Words |
HHepatitis C; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Genotype 1 |
| Core Tip |
The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), HCV NS4/4A protease inhibitor ABT-450 (paritaprevir, PTV), CYP3A inhibitor ritonavir (r) and non-nucleoside NS5B polymerase inhibitor ABT-333 (dasabuvir, DSV) (OBV/PTV/r + DSV) with or without ribavirin (RBV) is an approved direct-acting antiviral regimen less frequently studied in an all-comers population. This study included 96 all-comers; many had comorbidities (44.2% hypertensive, 33.7% obese, 20.2% cirrhotic) and 16% previously failed HCV treatment. In these patients, 12 or 24-wk of OBV/PTV/r + DSV +/- RBV was highly effective (99% sustained virologic response for 12 wk treatment), tolerable and resulted in better mental and physical health. |
| Publish Date |
2019-05-14 07:58 |
| Citation |
Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M and Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i18.2229 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
